Abstract | OBJECTIVE: The aim of this study was to evaluate acute and long-term morbidity, recurrence rate, and overall survival in patients with multiple groin lymph node metastases treated with postoperative chemotherapy. METHODS: Patients affected by FIGO stages III, IVA, and IVB (pelvic lymph nodes only) submitted to surgery were then treated with four cycles of cisplatin 100 mg/m(2) given 21 days apart. Toxicity, overall, and disease-free survival were evaluated. RESULTS: Fourteen patients were evaluated. Median patients age was 58 (range 48-82). Median performance status was 0 (0-2). All patients completed the treatment. No treatment-related deaths occurred. Only two patients suffered from grade 4 neutropenia during chemotherapy. Three patients suffered from long-term severe lymphedema. Four patients suffered a disease recurrence. Three of these patients were subjected to surgery with no severe postoperative complications. Two of the latter patients are still alive. At a median follow-up of 57.5 months (range 23-79 months) actuarial 3-year overall survival and progression-free survival are 86% and 71%, respectively. CONCLUSIONS: In patients affected by vulvar cancer with multiple lymph node metastases, radical surgery followed by chemotherapy is a feasible strategy, with an acceptable short- and long-term complication rate. Results in terms of overall survival and disease-free survival are promising. Furthermore, due to absence of local long-term tissue toxicity, this strategy allows physicians to surgically treat regional lymph node recurrence safely.
|
Authors | Filippo Bellati, Roberto Angioli, Natalina Manci, Marzio Angelo Zullo, Ludovico Muzii, Francesco Plotti, Stefano Basile, Pierluigi Benedetti Panici |
Journal | Gynecologic oncology
(Gynecol Oncol)
Vol. 96
Issue 1
Pg. 227-31
(Jan 2005)
ISSN: 0090-8258 [Print] United States |
PMID | 15589606
(Publication Type: Clinical Trial, Journal Article)
|
Chemical References |
- Antineoplastic Agents
- Cisplatin
|
Topics |
- Aged
- Aged, 80 and over
- Antineoplastic Agents
(adverse effects, therapeutic use)
- Carcinoma, Squamous Cell
(drug therapy, pathology, surgery)
- Cisplatin
(adverse effects, therapeutic use)
- Combined Modality Therapy
- Disease-Free Survival
- Female
- Humans
- Lymph Node Excision
- Lymph Nodes
(pathology, surgery)
- Lymphatic Metastasis
- Middle Aged
- Neoplasm Recurrence, Local
- Vulvar Neoplasms
(drug therapy, pathology, surgery)
|